Navigation Links
Novartis Drug SOM230 is First Medical Therapy to Show Efficacy in a Phase III Trial in Cushing's Disease, a Debilitating Hormonal Disorder
Date:9/21/2010

achieved normalization of UFC after six months without dose up-titration relative to randomized dose(1). UFC is typically used to diagnose and monitor Cushing's disease. In this test, urine is collected over 24 hours to assess average cortisol secretion(2). The primary endpoint was met for the higher dose tested (900ug sc twice daily)(1). Secondary endpoints included safety, time to response, response duration and changes from baseline in clinical signs, symptoms, tumor volume and health-related quality of life(10).

After six months, the primary efficacy responder rate was 26.3% (95% confidence interval [CI], 16.6 to 35.9) and 14.6% (95% CI, 7.0 to 22.3), respectively, for the 900ug and 600ug groups. Based on pre-specified criteria (lower bound of 95% CI >15%), the 900ug group met the primary endpoint and the 600ug group did not meet the primary endpoint. After 12 months, the proportion of responders regardless of dose up-titration was 13.4% and 25.0%, respectively, for the 600ug and 900ug groups. The median reduction in UFC after six months was 47.9% for both groups. The median reduction in UFC after 12 months was 67.6% (600ug) and 62.4% (900ug). Patients who showed little to no improvement in UFC levels (<50% reduction from baseline) by month two were unlikely to show improvement by month six or 12. The most frequently reported adverse events suspected by the investigators to be related to the study drug were diarrhea (58%), nausea (46.9%), hyperglycemia (38.9%), cholelithiasis (29.6%), abdominal pain (20.4%), diabetes mellitus (17.9%), fatigue (11.7%) and increased glycosylated hemoglobin (10.5%), with most events being Grade 1-2. Overall, the tolerability profile of SOM230 is similar to other somatostatin analogs with the exception of the greater degree of hyperglycemia, which appears manageable with early detection and appropriate intervention following established treatment guidelines. As may be expected with a treatment that lowers co
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... -- RESMED INC. (NYSE: RMD ) today announced that ... results on Thursday, January 22, 2015, after the New York ... will be issued after 1:00 p.m. US Pacific Time and ... and future outlook. The earnings call is scheduled ... live webcast of the call can be accessed on ResMed,s ...
(Date:12/19/2014)... , Dec. 18, 2014 Since last ... the site now known as the leading online black ... seen explosive growth in its offering of drugs and ... Alliance show the takedowns did succeed in lowering the ... last review of the markets in August. But some ...
(Date:12/19/2014)... LYON, France , Dec. 19, 2014 ... ) and Adocia (Euronext Paris: FR0011184241 – ADOC) today ... ultra-rapid insulin, known as BioChaperone Lispro, for treatment in ... Lispro relies on Adocia,s proprietary BioChaperone® technology and is ... Adocia will develop BioChaperone Lispro with the goal of ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
... Inc. (Nasdaq: STXS ) today announced that executive ... Conference on Tuesday, September 28, 2010 at 8:30 a.m. ET ... an overview of the Company,s business strategy and recent corporate ... invitation only. A live audio and slides webcast of Stereotaxis, ...
... BEDFORD, Mass., Sept. 23 Instrumentation Laboratory (IL), today announced ... on Wednesday, October 13, 2010 at the Grand Hyatt Nusa ... am to 12:00 pm, local time.  The forum will focus ... hemostasis.  All healthcare professionals, practicing in the Asia Pacific region ...
Cached Medicine Technology:Stereotaxis to Present at the JMP Securities Healthcare Conference 2Stereotaxis to Present at the JMP Securities Healthcare Conference 3Instrumentation Laboratory to Host 2nd Asia Pacific Hemostasis Forum 2Instrumentation Laboratory to Host 2nd Asia Pacific Hemostasis Forum 3Instrumentation Laboratory to Host 2nd Asia Pacific Hemostasis Forum 4
(Date:12/19/2014)... Montrose, Colorado (PRWEB) December 20, 2014 It’s ... many, travel is something that is put to the wayside ... those who still have that travel “itch” and that burning ... Inn Montrose accommodates families on their journey to Telluride with ... trip, get visitors to and from the resort, and ensure ...
(Date:12/19/2014)... December 19, 2014 Energy Textiles ... are now available. Celliant, the world’s leading responsive ... and pillowcases. , There are a number of ... circulation, increased oxygenation and balanced body temperature; which ... and pain relief; enhanced athletic performance; and overall ...
(Date:12/19/2014)... 2014 SuperCloset raises the bar once ... continues to offer indoor growers the most efficient and ... new SuperClone Rooms with the award winning SuperRooms ... hydroponic grow room setup. , The SuperClone Room features ... SuperCloner 50 . The SuperClone Room ...
(Date:12/19/2014)... 20, 2014 An evening dress is perfect ... lady’s closet. Discount-Dress.com, a distinguished dresses retailer, has unveiled its ... dresses in this great shopping platform. Customers can ... staff's hard work, Discount-Dress.com has been accepted and praised by ... and easier shopping stage for clients. In order to expand ...
(Date:12/19/2014)... (HealthDay News) -- New research warns parents that buying an older ... Nearly half of teen drivers killed in the United States ... 11 years old and often lacked important safety features that are ... teen drivers killed in crashes were in cars at least six ... old, 31 percent were in cars 11 to 15 years old, ...
Breaking Medicine News(10 mins):Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2Health News:Older Cars a Bad Choice for Younger Drivers 2
... who are diagnosed with bone cancer could benefit from better ... University of Nottingham. The Bone Cancer Research Trust launches ... project at the University which is testing a theory that ... Researchers at the School of Clinical Sciences, Division of ...
... Reporter , MONDAY, Oct. 11 (HealthDay News) -- The ... involving human embryonic stem cells has been injected with ... patient, being cared for at the Shepherd Center in ... The center specializes in treating these types of injuries. ...
... last six months of life has become progressively more expensive ... the United States and older adults in Canada, with a ... life in both countries, according to two reports posted online ... issue of Archives of Internal Medicine , one of ...
... intravitreous (into the eye) injection of a chemotherapy drug ... against the eye diseasedo not appear to be associated ... when compared with existing therapies, according to a report ... , one of the JAMA/Archives journals. "More than ...
... Oct. 11 (HealthDay News) -- Women with epilepsy may be at ... The study included 375 women who planned to have a ... or for up to 10 years. During the study period, 62 ... among women with epilepsy was more than twice the 15 percent ...
... of a computer or television screen are more likely to ... The PEACH project, a study of over a 1,000 ... spent in front of a screen as well as their ... children,s sedentary time and moderate physical activity. The results ...
Cached Medicine News:Health News:Hope for a new treatment for bone cancer 2Health News:First Patient Treated in U.S.-Approved Embryonic Stem Cell Trial 2Health News:First Patient Treated in U.S.-Approved Embryonic Stem Cell Trial 3Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 2Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 3Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 4Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 5Health News:Certain new therapies for age-related eye disease do not appear to increase heart risks 2Health News:Study Sees Link Between Epilepsy, Infertility 2Health News:Screen time linked to psychological problems in children 2
The ultimate combination of comfort, convenience and affordability, recommended for daily wear, also approved for extended wear (1-7 days)....
SofLens Multi-Focal with unique Natra-Sight Optics designed to provide broad transition for near, intermediate and far vision, SofLens Multi-Focal lenses offer crisp, clear vision at all distances....
... With the Hertel, the unit ... and held firmly against the ... with the center of the ... the two temporal orbital walls, ...
Fastest, easiest and least expensive method for measuring exophthalmos. By sighting at right angles, this device eliminates parallax and allows the clinician to measure the amount of protrusion or bu...
Medicine Products: